

IN THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A humanized antibody that binds ICAM-1, ~~said antibody selected from:~~ comprising SEQ ID NO:5 and 7 (HumB), or a subsequence thereof, wherein a variable framework region of the humanized antibody has had at least one non-human amino acid substituted with a human amino acid.
2. (Cancelled)
3. (Currently Amended) The antibody subsequence of ~~claim 2~~ claim 1, wherein the antibody subsequence comprises a single chain, Fv, Fab, Fab' or (Fab)₂ fragment.
4. (Currently Amended) The humanized antibody of claim 1, ~~said wherein antibody having one or more amino acid substitutions, provided that said substitution when in the variable framework region is an amino acid based upon a human consensus variable framework region sequence, and said substituted antibody is capable of binding an ICAM-1 epitope.~~
5. (Currently Amended) A humanized antibody that binds ICAM-1 and inhibits ~~pathogen~~ human rhinovirus (HRV) infection of cells expressing ICAM-1, wherein a variable framework region of the humanized antibody has had one or more non-human amino acids substituted with an amino acid of a human consensus variable framework region sequence, and wherein the protective efficacy against HRV is at least equivalent to greater than mouse monoclonal antibody denoted as 1A6.
6. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 2 times greater than ~~the~~ non-humanized 1A6 antibody.
7. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 5 times greater than ~~the~~ non-humanized 1A6 antibody.
8. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 10 times greater than ~~the~~ non-humanized 1A6 antibody.
9. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 20 times greater than ~~the~~ non-humanized 1A6 antibody.
10. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 30 times greater than ~~the~~ non-humanized 1A6 antibody.
11. (Cancelled)
12. (Cancelled)

13. (Currently Amended) The humanized antibody of claim 5, ~~wherein the antibody is an intact immunoglobulin molecule~~ comprising 2 full-length heavy chains and 2 full-length light chains.
14. (Cancelled)
15. (Currently Amended) The humanized antibody ~~of claim 14~~ subsequence of claim 1, wherein the antibody subsequence comprises a single chain, Fv, Fab, Fab' or (Fab)₂ fragment.
16. (Currently Amended) The humanized antibody of claim 1 or 5, wherein the humanized antibody is multispecific or multifunctional.
17. (Currently Amended) The humanized antibody of claim 1 or 5, wherein the humanized antibody is linked to one or more identical or different antibodies to form a multimer.
18. (Previously Presented) The humanized antibody of claim 17, wherein the multimer comprises a homo- or hetero-dimer, trimer, or tetramer.
19. (Previously Presented) The humanized antibody of claim 17, wherein the multimer is formed via a multimerization domain.
20. (Previously Presented) The humanized antibody of claim 19, wherein the multimerization domain comprises a human amino acid sequence.
21. (Currently Amended) The humanized antibody of claim 19, further comprising a linker located between the multimerization domain and the humanized antibody.
22. (Currently Amended) A humanized antibody that inhibits human rhinovirus (HRV) infection of cells comprising ~~the amino acid sequence set forth in any of SEQ ID NO:5 and 7 (HumB)~~ or a subsequence thereof, wherein a variable framework region of said subsequence the humanized antibody has had one or more non-human amino acids substituted with an amino acid of a human consensus variable framework region sequence.
23. (Currently Amended) The humanized antibody of claim 22, ~~wherein the antibody is an immunoglobulin molecule~~ comprising 2 full-length heavy chain polypeptides and 2 full-length light chain polypeptides.
24. (Previously Presented) The humanized antibody of claim 22, wherein the subsequence comprises a single chain, Fv, Fab, Fab' or (Fab)₂ fragment.
25. (Currently Amended) The humanized antibody of claim 22, wherein the humanized antibody is linked with other identical or different antibodies to form a multimer.

26. (Previously Presented) The humanized antibody of claim 25, wherein the multimer comprises a homo- or hetero-dimer, trimer, or tetramer.
27. (Previously Presented) The humanized antibody of claim 25, wherein the different antibodies are human, humanized or non-human.
28. (Currently Amended) A nucleic acid sequence encoding a humanized antibody of claim 1 or 22 or a subsequence thereof, ~~wherein the variable framework region of said subsequence has one or more amino acids of a human consensus variable framework region sequence.~~
29. (Previously Presented) An expression cassette comprising the nucleic acid sequence of claim 28 operably linked to an expression control element.
30. (Previously Presented) A vector comprising the nucleic acid sequence of claim 29.
31. (Currently Amended) The vector of claim [[29]] 30, wherein the nucleic acid sequence is operably linked to an expression control element.
32. (Previously Presented) A cell comprising the nucleic acid sequence of claim 28.
33. (Currently Amended) The cell of claim [[31]] 32, wherein the cell is prokaryotic or eukaryotic.
34. (Previously Presented) A pharmaceutical composition comprising a humanized antibody of claim 1 or 5, and a pharmaceutically acceptable carrier.
35. (Previously Presented) The pharmaceutical composition of claim 34, wherein the carrier is compatible with inhalation or nasal delivery to a subject.
36. (Currently Amended) A method of inhibiting ~~pathogen~~ HRV infection of a cell comprising contacting ~~a pathogen~~ HRV or a cell with an amount of a humanized antibody of claims 1 or 5, sufficient to inhibit ~~pathogen~~ HRV infection of the cell.
37. (Previously Presented) The method of claim 36, wherein the cell is present in a subject.
38. (Previously Presented) The method of claim 37, wherein the cell is an epithelial cell.
39. (Previously Presented) The method of claim 37, wherein the cell expresses ICAM-1.
40. (Amended) A method of inhibiting HRV infection of a cell comprising contacting HRV or a cell susceptible to HRV infection with an amount of a humanized antibody of claim 22 effective to inhibit HRV infection of the cell.
41. (Previously Presented) The method of claim 40, wherein the cell is present in a subject.
42. (Previously Presented) The method of claim 41, wherein the subject has or is at risk of having asthma.

43. (Previously Presented) The method of claim 40, wherein the antibody binds to an antigen present on the surface of the cell.
44. (Previously Presented) The method of claim 40, wherein the cell expresses ICAM-1.
45. (Previously Presented) The method of claim 40, wherein the cell is an epithelial cell.
46. (Previously Presented) The method of claim 40, wherein the humanized antibody is administered locally.
47. (Currently Amended) The method of claim 40, wherein the humanized antibody is administered via inhalation or ~~intranassally~~ intranasally.
48. (Currently Amended) A method of inhibiting HRV infection, inhibiting HRV progression or treating HRV infection of a subject comprising administering to a subject having or at risk of having HRV infection an amount of a humanized antibody of claim 22 effective to ~~inhibit~~, inhibit progression or treat HRV infection of the subject.
49. (Previously Presented) The method of claim 48, wherein the humanized antibody is administered locally.
50. (Currently Amended) The method of claim 48, wherein the humanized antibody is administered via inhalation or ~~intranassally~~ intranasally.
51. (Previously Presented) The method of claim 48, wherein the subject has or is at risk of having asthma.
52. (Currently Amended) The method of claim 48, wherein the subject is a newborn or between the ages of 1 to 5, 5 to 10 or 10 to 18 years.
53. (Currently Amended) A method of decreasing or inhibiting ~~one or more symptoms a~~ symptom of the common cold in a subject comprising administering to a subject having a common cold an amount of a humanized antibody of claim 22 effective to decrease or inhibit one or more symptoms of the common cold in the subject.
54. (Previously Presented) The method of claim 53, wherein the humanized antibody is administered locally.
55. (Currently Amended) The method of claim 53, wherein the humanized antibody is administered via inhalation or ~~intranassally~~ intranasally.
56. (Previously Presented) The method of claim 53, wherein the subject has or is at risk of having asthma.

57. (Currently Amended) The method of claim 53, wherein the subject is a newborn or between the ages of 1 to 5, 5 to 10 or 10 to 18 years.
58. (Cancelled)
59. (Cancelled)
60. (Currently Amended) The humanized antibody of claim 4, wherein said framework region substitution comprises 5-10 human amino acids.
61. (Currently Amended) The humanized antibody of claim 4, wherein said framework region substitution comprises 3-5 human amino acids.
62. (Currently Amended) The humanized antibody of claim 4, wherein said framework region substitution comprises 1-3 human amino acids.
63. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody binds ICAM-1 with increased affinity relative to unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
64. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 4-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
65. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 5-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
66. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 5 to 8-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
67. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 5 to 10-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
68. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 8 to 15-fold greater than unsubstituted humanized antibody

having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.

69. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 10 to 20-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
70. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 20 to 40-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
71. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 50 to 100-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
72. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 100-fold or greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6.
73. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody binds ICAM-1 with an affinity ~~at least equivalent to~~ greater than mouse monoclonal antibody denoted as 1A6.
74. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody binds ICAM-1 with increased affinity relative to mouse monoclonal antibody denoted as 1A6.
75. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 4-fold greater than mouse monoclonal antibody denoted as 1A6.
76. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 5- fold greater than mouse monoclonal antibody denoted as 1A6.

77. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 5 to 8-fold greater than mouse monoclonal antibody denoted as 1A6.
78. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 5 to 10-fold greater than mouse monoclonal antibody denoted as 1A6.
79. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 8 to 15-fold greater than mouse monoclonal antibody denoted as 1A6.
80. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 10 to 20-fold greater than mouse monoclonal antibody denoted as 1A6.
81. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 20 to 40-fold greater than mouse monoclonal antibody denoted as 1A6.
82. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 50 to 100-fold greater than mouse monoclonal antibody denoted as 1A6.
83. (Currently Amended) The humanized antibody of claim 4, wherein the substituted antibody has an ICAM-1 binding affinity 100-fold or greater than mouse monoclonal antibody denoted as 1A6.